258 related articles for article (PubMed ID: 11062721)
1. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
3. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
4. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.
O-Charoenrat P; Rhys-Evans PH; Eccles SA
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):813-20. PubMed ID: 11448356
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
9. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
10. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma.
Wiegand S; Dünne AA; Müller HH; Mandic R; Barth P; Davis RK; Werner JA
Cancer; 2005 Jul; 104(1):94-100. PubMed ID: 15912516
[TBL] [Abstract][Full Text] [Related]
11. The matrix metalloproteinase system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):482-6. PubMed ID: 16338034
[TBL] [Abstract][Full Text] [Related]
12. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
13. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck.
Do NY; Lim SC; Im TS
Oncol Rep; 2004 Aug; 12(2):229-37. PubMed ID: 15254682
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; Hernández Vallejo G
Oral Oncol; 2005 Mar; 41(3):283-93. PubMed ID: 15743691
[TBL] [Abstract][Full Text] [Related]
16. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
[TBL] [Abstract][Full Text] [Related]
17. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma.
Hashimoto T; Uchida K; Okayama N; Imate Y; Suehiro Y; Hamanaka Y; Ueyama Y; Shinozaki F; Yamashita H; Hinoda Y
Cancer Lett; 2004 Jul; 211(1):19-24. PubMed ID: 15194213
[TBL] [Abstract][Full Text] [Related]
18. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
Hrabec E; Strek M; Nowak D; Hrabec Z
Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-2, -9 and -13 in cell lines and fresh biopsies of squamous cell carcinomas of the upper aerodigestive tract.
Dünne AA; Sesterhenn A; Gerisch A; Teymoortash A; Kuropkat C; Werner JA
Anticancer Res; 2003; 23(3B):2233-9. PubMed ID: 12894497
[TBL] [Abstract][Full Text] [Related]
20. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.
Mannello F
Cancer; 2003 Jan; 97(1):201-3; author reply 203-4. PubMed ID: 12491521
[No Abstract] [Full Text] [Related]
[Next] [New Search]
